Mechanisms of chemoresistance in cancer stem cells

Chemotherapy is one of the standard methods of treatment in many cancers. While chemotherapy is often capable of inducing cell death in tumors and reducing the tumor bulk, many cancer patients experience recurrence and ultimately death because of treatment failure. In recent years, cancer stem cells (CSCs) have gained intense interest as key tumor-initiating cells that may also play an integral role in recurrence following chemotherapy. As such, a number of mechanisms of chemoresistance have been identified in CSCs. In this review, we describe a number of these mechanisms of chemoresistance including ABC transporter expression, aldehyde dehydrogenase (ALDH) activity, B-cell lymphoma-2 (BCL2) related chemoresistance, enhanced DNA damage response and activation of key signaling pathways. Furthermore, we evaluate studies that demonstrate potential methods for overcoming chemoresistance and treating chemoresistant cancers that are driven by CSCs. By understanding how tumor-initiating cells such as CSCs escape chemotherapy, more informed approaches to treating cancer will develop and may improve clinical outcomes for cancer patients.

[1]  T. Reya,et al.  Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. , 2007, Cancer cell.

[2]  Kannappan,et al.  Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties , 2011, British Journal of Cancer.

[3]  G. Mor,et al.  Regulation of Inflammation by the NF‐κB Pathway in Ovarian Cancer Stem Cells , 2011, American journal of reproductive immunology.

[4]  I. Bisson,et al.  WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics , 2009, Cell Research.

[5]  L. Garraway,et al.  Clinical implications of the cancer genome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Scott,et al.  Aldehyde dehydrogenase activity as a functional marker for lung cancer. , 2009, Chemico-biological interactions.

[7]  Tohru Utsunomiya,et al.  Cancer stem cells in human gastrointestinal cancers , 2006, Human Cell.

[8]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[9]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[10]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[11]  I. Weissman,et al.  A role for Wnt signalling in self-renewal of haematopoietic stem cells , 2003, Nature.

[12]  I. Sugawara.  Expression and Functions of P‐glycoprotein (mdr 1 gene product) in Normal and Malignant Tissues , 1990, Acta pathologica japonica.

[13]  J. Marks,et al.  Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells , 2009, Oncogene.

[14]  O. Colvin,et al.  Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  N. Sládek.  Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact , 2003, Journal of biochemical and molecular toxicology.

[16]  A. Goga,et al.  Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment , 2011, Science Translational Medicine.

[17]  A. Krešo,et al.  Cancer stem cells in solid tumors: an overview. , 2009, Seminars in radiation oncology.

[18]  R. Chen,et al.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.

[19]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[20]  L. Doyle,et al.  Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.

[21]  B. Sikic,et al.  A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. , 2009, Leukemia research.

[22]  Y. Miao,et al.  Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. , 2011, Swiss medical weekly.

[23]  M. Hidalgo,et al.  Inhibition of Ataxia Telangiectasia‐ and Rad3 ‐Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor‐Initiating Cell Fraction , 2011, Stem cells.

[24]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[25]  M. Wicha,et al.  Single‐marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase , 2010, Head & neck.

[26]  E. Hammond,et al.  Targeting Hypoxic Cells through the DNA Damage Response , 2010, Clinical Cancer Research.

[27]  Edward Kai-Hua Chow,et al.  Oncogene‐specific formation of chemoresistant murine hepatic cancer stem cells , 2012, Hepatology.

[28]  T. Dale,et al.  The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.

[29]  S. Salani,et al.  Identification of a Primitive Brain–Derived Neural Stem Cell Population Based on Aldehyde Dehydrogenase Activity , 2006, Stem cells.

[30]  Cayetano Gonzalez.  Aurora-A in Cell Fate Control , 2002, Science's STKE.

[31]  G. Feldmann,et al.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development , 2009, Molecular Cancer Therapeutics.

[32]  A. Sonabend,et al.  Inhibition of Sonic Hedgehog and Notch Pathways Enhances Sensitivity of CD133+ Glioma Stem Cells to Temozolomide Therapy , 2011, Molecular medicine.

[33]  Liang Tang,et al.  Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. , 2008, Cancer research.

[34]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[35]  K. Chan,et al.  Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations , 2008, Molecular Cancer Research.

[36]  K. Roth,et al.  Mcl-1 deficiency results in peri-implantation embryonic lethality. , 2000, Genes & development.

[37]  A. Yoshida,et al.  Isolation and characterization of aldehyde dehydrogenase isozymes from usual and atypical human livers. , 1983, The Journal of biological chemistry.

[38]  Tetsuhiro Chiba,et al.  Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties , 2006, Hepatology.

[39]  T. Lawrence,et al.  Abstract 3919: Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition , 2011 .

[40]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[41]  H. Friedman,et al.  Cyclophosphamide resistance in medulloblastoma. , 1992, Cancer research.

[42]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[43]  Lye Mun Tho,et al.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.

[44]  J. Beckmann,et al.  The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway , 2009, Oncogene.

[45]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[46]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[47]  A. Strasser,et al.  The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy , 2011, Cell Death and Differentiation.

[48]  A. Bjartell,et al.  Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells , 2011, PloS one.

[49]  J. Hilton.  Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. , 1984, Cancer research.

[50]  M. Todaro,et al.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. , 2007, Cell stem cell.

[51]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[52]  Y. Takeda,et al.  Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma , 2009, British Journal of Cancer.

[53]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[55]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[56]  Gregory A. Wyant,et al.  Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy , 2012, Proceedings of the National Academy of Sciences.

[57]  P. Dollé,et al.  Retinoic acid signalling during development , 2012, Development.

[58]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[59]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[60]  E. Estey,et al.  The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells , 2002, British journal of haematology.

[61]  M. Asadi-lari,et al.  CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. , 2009, Cancer immunity.

[62]  T. Kondo,et al.  Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  M. Clarke,et al.  Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy , 2008, PloS one.

[64]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[65]  G. Duester,et al.  Molecular analysis of two closely related mouse aldehyde dehydrogenase genes: identification of a role for Aldh1, but not Aldh-pb, in the biosynthesis of retinoic acid. , 1999, The Biochemical journal.

[66]  K. Nakayama,et al.  Accelerated Neutrophil Apoptosis in Mice Lacking A1-a, a Subtype of the bcl-2–related A1 Gene , 1998, The Journal of experimental medicine.

[67]  H. Lai,et al.  c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin–ATP-binding cassette G2 signaling , 2013, Oncogene.

[68]  Tao Li,et al.  Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer , 2011, PloS one.

[69]  Peter T Masiakos,et al.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[70]  T. Reya,et al.  Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo , 2007 .

[71]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[72]  al. et,et al.  Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice , 1995, Science.

[73]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[74]  S. Korsmeyer,et al.  Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. , 1987, The Journal of clinical investigation.

[75]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[76]  K. Tanabe,et al.  Role of mitochondria as the gardens of cell death , 2006, Cancer Chemotherapy and Pharmacology.

[77]  A. Giaccia,et al.  Hypoxia Links ATR and p53 through Replication Arrest , 2002, Molecular and Cellular Biology.

[78]  J. Crowley,et al.  A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.

[79]  A. Capobianco,et al.  Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.

[80]  Li-Xuan Qin,et al.  gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. , 2009, Cancer research.

[81]  M. Todaro,et al.  Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. , 2010, Cancer research.

[82]  M. Ballmaier,et al.  Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line , 2007, Molecular and Cellular Biochemistry.

[83]  L. Sreerama,et al.  Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  N. Perkins,et al.  The diverse and complex roles of NF-κB subunits in cancer , 2012, Nature Reviews Cancer.

[85]  M. Schweder,et al.  Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. , 2000, The Journal of pharmacology and experimental therapeutics.

[86]  Y. Seong,et al.  Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells , 2012, International journal of oncology.

[87]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[88]  A. Cheung,et al.  Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential , 2007, Leukemia.

[89]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[90]  U. Kim,et al.  Progression from hormone dependence to autonomy in mammary tumors as an in vivo manifestation of sequential clonal selection. , 1975, Cancer research.

[91]  V. Ling,et al.  P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. , 1997, European journal of biochemistry.

[92]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[93]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[94]  C. Print,et al.  Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[95]  W. Matsui,et al.  Hedgehog pathway as a drug target: Smoothened inhibitors in development , 2012, OncoTargets and therapy.

[96]  R. Mehrazin,et al.  Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway , 2012, PloS one.

[97]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[98]  P. Nowell,et al.  A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. , 1984, Proceedings of the National Academy of Sciences of the United States of America.